Home > Oncology > Positive phase-3 data for PARP inhibitor niraparib in ovarian cancer

Positive phase-3 data for PARP inhibitor niraparib in ovarian cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
Society of Gynecologic Oncology (SGO) Annual Meeting
Reuters Health - 25/03/2022 - Maintenance therapy with the PARP inhibitor niraparib provided statistically significant and clinically meaningful improvement in progression-free survival (PFS), regardless of biomarker status, in women with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer enrolled in the PRIME trial. "The PRIME data continue to support niraparib monotherapy as the standard of care after first-line platinum-based chemotherapy regardless of biomarker status," Dr. Alan Sandler, president and head of global development, oncology at Zai Lab, the study's funder, said in a news release. The phase-3 study was presented at the Society of Gynecologic Oncology annual meeting. The study enrolled 384 women with advanced ovarian cancer who achieved complete or partial response to first-line platinum-based chemotherapy and received primary or interval cytoreductive surgery, irrespective of residual-disease status after ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on